Page 120 - Haematologica Vol. 107 - September 2022

ARTICLE - iLLUMINATE: final analysis
C. Moreno et al.
funding from AbbVie and Janssen; and participated in speakers bureaus for AbbVie and Janssen. RG has received honoraria from Celgene, Roche, Merck, AstraZeneca, No- vartis, Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Sandoz, AbbVie, Gilead, and Daiichi Sankyo; has provided consulting/advisory services for Celgene, Novartis, Roche, Bristol Myers Squibb, Takeda, AbbVie, AstraZeneca, Jan- ssen, Merck Sharp & Dohme, Merck, Gilead, and Daiichi Sankyo; has received research funding from Celgene, Merck, Takeda, AstraZeneca, Novartis, Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Sandoz, Gilead, and Roche; has received travel or accommodation funds from Roche, Amgen, Janssen, AstraZeneca, Novartis, Merck Sharp & Dohme, Celgene, Gilead, Bristol Myers Squibb, and AbbVie. FD has had a consulting/advisory role for AbbVie, AstraZe- neca, Roche, and Amgen; has received research funding from AbbVie, Janssen, Pharmacyclics LLC, an AbbVie com- pany, and AstraZeneca; has participated in speakers bu- reaus for Janssen, AbbVie, and Amgen; and has received travel or accommodation expenses from Amgen, Janssen, AbbVie, and Pfizer. AT has received honoraria from Jan- ssen, AbbVie, AstraZeneca, and BeiGene; and has partici- pated in speakers bureaus for Janssen, BeiGene, AstraZeneca, and AbbVie. BA has nothing to disclose. LL has provided consulting/advisory services for AbbVie and Janssen. MS has received honoraria from AbbVie, Roche, Janssen-Cilag, Gilead, and Acerta Pharma; has played a consulting/advisory role for AbbVie; has participated in speakers bureaus for AbbVie, Roche, Janssen-Cilag, and Gilead; and has received travel or accommodation expen- ses from AbbVie, Roche, Janssen-Cilag, and Gilead. JN has played a consulting/advisory role for Amgen, Takeda, Roche, Celgene, Pfizer, and Novartis; and has received tra- vel or accommodation expenses from Amgen and Janssen. VS is employed by Eco-Safety Medical Center; has stock ownership in Portola Pharmaceuticals, Gilead, Moderna, and Clovis Oncology; has received research funding from Janssen; and has received travel or accommodation ex- penses from AbbVie and Janssen. DG has received hono- raria from Janssen-Cilag; and has played a consulting/advisory role for Janssen-Cilag. JGG has recei- ved honoraria from AbbVie, Roche, Bristol Myers Squibb, Janssen, and AstraZeneca; has provided consulting/advi- sory services for AbbVie, Janssen, and Gilead; and received research funding from Janssen, AstraZeneca, and Celgene. KK is employed by Pharmacyclics LLC, an AbbVie Company; and owns stock in Pharmacyclics LLC, an AbbVie Company, and Gilead. SD has been employed by Pharmacyclics LLC, an AbbVie Company. and Horizon Therapeutics; and has stock ownership in AbbVie, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Exelixis, Revance, Horizon Therapeutics,
and Myovant Science. EH and JPD are employed by Phar- macyclics LLC, an AbbVie Company; and own stock in Abb- Vie. IWF has provided consulting/advisory services for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Thera- peutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics LLC, an AbbVie Company, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, and Yingli Pharma; and has received research funding from AbbVie, Acerta Pharma, Agios, ArQule, Astra- Zeneca, BeiGene, Calithera Biosciences, Celgene, Constel- lation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, No- vartis, Pfizer, Pharmacyclics LLC, an AbbVie Company, Por- tola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Pharma, Unum Therapeutics, and Verastem.
Contributions
As members of the Steering Committee, CM, DG, JGG, and IWF collaborated with the study sponsors to design the study and protocol; CM, RG, RD, AT, BA, LL, MS, JN, VS, DG, JGG, and IWF collected the study data; SD analyzed the data; KK collected and tested the high-risk genomic factor data for the study; SD, EH, and JD confirmed the accuracy of the data and compiled it for analysis. All authors had access to the data and were involved in the interpretation of data, contributed to the manuscript review and revi- sions, and approved the final version for submission.
Acknowledgments
The authors thank the patients who participated in this trial and their families. The authors also thank Cindi A. Hoover, PhD, for medical writing, which was supported by Pharmacyclics LLC, an AbbVie Company.
Funding
Pharmacyclics LLC, an AbbVie Company, sponsored and designed the study. Study investigators and their research teams collected the data. The sponsor confirmed data ac- curacy and analyzed the data. Medical writing was funded by the sponsor.
Data-sharing statement
Requests for access to individual participant data from cli- nical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Ac- cess (YODA) Project site at http://yoda.yale.edu.
Haematologica | 107 September 2022
2119